Lanthanide Radionuclide Production

稀土放射性核素生产

基本信息

批准号：
7538452
负责人：
JOHN M ALFORD
金额：
$ 17.93万
依托单位：
TDA RESEARCH, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-01 至 2010-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7538452
关键词：
Acids Antibodies Area Binding Businesses Carbon Cell Nucleus Characteristics Chelating Agents Chemicals Development Discipline of Nuclear Medicine District of Columbia Educational workshop Engineering Environment Evaluation Extravasation Fast Neutrons Fullerenes Gamma Rays Generations Government Half-Life Human Hydrochloric Acid Ion Exchange Ions Isotopes Label Laboratories Lanthanoid Series Elements Left Lutetium Malignant Neoplasms Measures Metals Methods Missouri Monoclonal Antibodies Natural graphite Neoplasm Metastasis Neutrons Nuclear Reactors Persons Phase Positioning Attribute Procedures Process Production Property Public Health Purpose Quality Control Quartz Radiation therapy Radioactive Radioimmunotherapy Radioisotopes Radiopharmaceuticals Rate Reaction Reagent Research Route Running Sampling Scheme Series Soot Source Spectrum Analysis Sublimation - mental defence mechanism Techniques Technology Transfer Testing Time Titrations Trace metal Tube United States Food and Drug Administration Universities Work base cancer therapy chelation chemical bond cost cost effective day desire improved irradiation milligram next generation prevent retinal rods success

项目摘要

DESCRIPTION (provided by applicant): Major advances have recently been made in the development of monoclonal antibody-based radioimmunotherapy cancer treatments, and several of these next generation antibody treatments have demonstrated good efficacy in human trials and are currently awaiting FDA approval. With this new generation of highly engineered monoclonal antibodies comes the need for a wider array of commercially available radionuclides. Unfortunately, methods for producing the next generation of radioisotopes has not kept pace. This Small Business Technology Transfer Phase I project will develop an improved method for the production of radionuclides used in radiopharmaceuticals. The method will allow the economical production of a wide array of lanthanide radionuclides which can subsequently be employed for radioimmunotherapy treatments. During Phase I, a new type of Szilard-Chalmers process using pecialized lanthanide chelates will be developed and tested. The new lanthanide chelate will be synthesized in bulk quantities and then the entire production process will be tested using neutron activation at the Missouri University Research Reactor. PUBLIC HEALTH RELEVANCE: Current radioisotope production relies on isotopically purified starting materials that must be irradiated at the highest flux (most expensive) position in the central core of the nuclear reactor. If successful, TDA's new Szilard-Chalmers process is expected to lower production costs by allowing the use of non-isotopically purified starting materials that are neutron irradiated at the more cost effective low .nux positions in the reactor.

描述（由申请人提供）：最近在基于单克隆抗体的放射免疫治疗癌症治疗的开发方面取得了重大进展，其中几种下一代抗体治疗已在人体试验中表现出良好的疗效，目前正在等待 FDA 批准。随着新一代高度工程化的单克隆抗体的出现，需要更广泛的商用放射性核素。不幸的是，生产下一代放射性同位素的方法并没有跟上步伐。该小型企业技术转让第一阶段项目将开发一种改进的方法来生产放射性药物中使用的放射性核素。该方法将能够经济地生产多种镧系元素放射性核素，这些元素随后可用于放射免疫疗法。在第一阶段，将开发和测试一种使用特殊镧系元素螯合物的新型 Szilard-Chalmers 工艺。新的镧系元素螯合物将被批量合成，然后整个生产过程将在密苏里大学研究堆中使用中子活化进行测试。公众健康相关性：目前的放射性同位素生产依赖于同位素纯化的起始材料，这些起始材料必须在核反应堆中心的最高通量（最昂贵）的位置进行辐照。如果成功，TDA 的新 Szilard-Chalmers 工艺预计将通过允许使用非同位素纯化的起始材料来降低生产成本，这些起始材料在反应堆中更具成本效益的低 .nux 位置进行中子辐照。